Decreased glutathione biosynthesis contributes to EGFR T790M-driven erlotinib resistance in non-small cell lung cancer

Epidermal growth factor receptor (EGFR) inhibitors such as erlotinib are novel effective agents in the treatment of EGFR-driven lung cancer, but their clinical impact is often impaired by acquired drug resistance through the secondary T790M EGFR mutation. To overcome this problem, we analysed the me...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Cell Discov
Huvudupphovsmän: Li, Hongde, Stokes, William, Chater, Emily, Roy, Rajat, de Bruin, Elza, Hu, Yili, Liu, Zhigang, Smit, Egbert F, Heynen, Guus JJE, Downward, Julian, Seckl, Michael J, Wang, Yulan, Tang, Huiru, Pardo, Olivier E
Materialtyp: Artigo
Språk:Inglês
Publicerad: Nature Publishing Group 2016
Ämnen:
Article
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC5037574/
https://ncbi.nlm.nih.gov/pubmed/27721983
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/celldisc.2016.31
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk